ABT stock sentiment todayAbbott Laboratories
Sentiment verdict
Gossip first, financials second — NEUTRAL at 75% confidence.
Last updated · cached analysis, refreshes periodically
ABT
Abbott LaboratoriesAbbott is a diversified defensive play balancing strong medical device growth against a post-pandemic diagnostic hangover.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for ABT. Not financial advice.
Price · last 12 months
Gossip
The narrative is currently dominated by a 'tug-of-war' between the explosive growth of the FreeStyle Libre (CGM) system and lingering legal overhangs regarding infant formula litigation. While the medical device segment is lauded, the waning of COVID-19 testing revenue continues to weigh on year-over-year comparisons.
- ·Growth of FreeStyle Libre 3 adoption
- ·Infant formula NEC litigation uncertainty
- ·Recovery in elective surgical procedures boosting heart valve sales
- ·Stabilization of Nutrition segment margins
Financial
Abbott maintains an elite balance sheet and is a Dividend King with 50+ years of increases. While top-line growth looks muted due to the diagnostic cliff, core organic growth (excluding COVID testing) remains robust at high single digits.
- ·Forward P/E ratio: ~22x (Trading slightly above historical averages)
- ·Dividend Yield: ~2.1%
- ·Operating Margin: ~20-22%
- ·Debt-to-Equity: ~0.45 (Very conservative leverage)
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Hollow — insiders are stepping back and the register is short-horizon.
- ·Insiders sold a net $46.9M on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Legal liabilities from NEC lawsuits involving Similac
- ·Continued decline in COVID-19 testing demand
- ·Potential GLP-1 impact on long-term medical device demand (though arguably overblown)
Peer temperature
How direct competitors stack up against ABT right now.
- COLDMDTMedtronic
COLDER — lower organic growth rates and persistent operational execution issues compared to Abbott’s management track record.
See full analysis → - HOTDXCMDexcom
HOTTER — trading at a higher premium but offers pure-play, faster growth in the CGM space without Abbott's legacy legal baggage.
See full analysis → - NEUTRALTMOThermo Fisher Scientific
NEUTRAL — similar high-quality defensive profile but more exposed to the current slowdown in bioprocessing and life sciences capital spending.
See full analysis →
- ABT+7.5%
- MDT+11.9%
- DXCM-4.6%
- TMO+3.3%
Analyst price target
Consensus average of 18 analysts · median 120.00
Source: StockAnalysis.com · updated 2026-10-23
AI-generated analysis for informational purposes only. Not financial advice.